How Nucala works
Nucala targets IL-5 and is indicated as an add-on treatment for adult, adolescent and paediatric patients (aged 6 or above) with severe refractory eosinophilic asthma. 1 Nucala is the only anti-IL-5 indicated for severe refractory eosinophilic asthma to demonstrate lasting reduction in exacerbations and OCS dose for up to 4.5 years*. 2 3 4 5 6
IL-5 is the major cytokine responsible for the growth, differentiation, recruitment, activation and survival of eosinophils. 7
Nucala is the only anti-IL-5 to demonstrate sustained reduction in blood eosinophils, without complete depletion, for up to 4.5 years. 4
The Evolution of Eosinophils
IL, interleukin, OCS, oral corticosteroids
Nucala is generally well tolerated. Very commonly or commonly reported adverse reactions in clinical trials included: headache; back pain; local injection site reactions; systemic administration-related and hypersensitivity reactions (which can occur after a long duration of treatment); LRTI; UTI; pharyngitis; nasal congestion; upper abdominal pain; eczema and pyrexia. 1
*Range: 4 weeks to 4.5 years
- Nucala SmPC 2020, accessed August 2020. Available at www.medicines.ie.
- Khurana S, et al. Clin Ther. 2019; 41(10):2041-2056.
- Ortega HG et al. N Engl J Med 2014; 371:1198–1207.
- Khatri et al. 2019; J Allergy Clin Immunol; 143 (5):1742-1751
- Chupp GL et al. Lancet Respir Med 2017; 5:390–400
- Bel EH et al. N Engl J Med 2014; 371:1189-1197.
- Weller PF, Spencer LA. Nat Rev Immunol 2017; 17:746-760.
- Price D et al. J Asthma Allergy 2016; 9:1-12.
- Garcia G et al. Eur Respir Rev 2013; 22:251-257.
- Wen T, Rothenburg ME. Microbiol Spectr 2016; doi: 10.1128/microbiolspec.MCHD-0020-2015.